Geron Positive Spinal Cord Injury Data

<p>By Jon C. Ogg, Nov. 7, 2007 ( Geron Corp. (NASDAQ:GERN) is trading up in pre-market activity on news that would have been much more eagerly received back in the emergence of stem cell news.&nbsp; Geron announced that data shows its human embryonic stem cell based therapeutic candidate for spinal cord injury GRNOPC1 survives and exhibits durable and robust human remyelination in spinal cord-injured rats.&nbsp; The duration was for at least nine months following a single injection…</p>